Author:
Wong Dean F,Brašić James R,Singer Harvey S,Schretlen David J,Kuwabara Hiroto,Zhou Yun,Nandi Ayon,Maris Marika A,Alexander Mohab,Ye Weiguo,Rousset Olivier,Kumar Anil,Szabo Zsolt,Gjedde Albert,Grace Anthony A
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference70 articles.
1. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K et al (2003). Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61: 310–315.
2. American Psychiatric Association (2004). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text revision (DSM-IV-TM™), American Psychiatric Association: Washington, DC.
3. Baumann MH, Danos P, Krell D, Diekmann S, Leschinger A, Stauch R et al (1999). Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. J Neuropsychiatry Clin Neurosci 11: 71–78.
4. Bruun RD, Budman CL (1996). Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 57: 29–31.
5. Butler IJ, Koslow SH, Seifert Jr WE, Caprioli RM, Singer HS (1979). Biogenic amine metabolism in Tourette syndrome. Ann Neurol 6: 37–39.